Find in Library
Search millions of books, articles, and more
Indexed Open Access Databases
Validation of miRNA signatures for ovarian cancer earlier detection in the pre-diagnosis setting using machine learning approaches
oleh: Konrad Stawiski, Renée T. Fortner, Renée T. Fortner, Luca Pestarino, Luca Pestarino, Sinan U. Umu, Rudolf Kaaks, Trine B. Rounge, Trine B. Rounge, Kevin M. Elias, Kevin M. Elias, Wojciech Fendler, Wojciech Fendler, Hilde Langseth, Hilde Langseth
Format: | Article |
---|---|
Diterbitkan: | Frontiers Media S.A. 2024-06-01 |
Deskripsi
IntroductionEffective strategies for early detection of epithelial ovarian cancer are lacking. We evaluated whether a panel of 14 previously established circulating microRNAs could discriminate between cases diagnosed <2 years after serum collection and those diagnosed 2–7 years after serum collection. miRNA sequencing data from subsequent ovarian cancer cases were obtained as part of the ongoing multi-cancer JanusRNA project, utilizing pre-diagnostic serum samples from the Janus Serum Bank and linked to the Cancer Registry of Norway for cancer outcomes.MethodsWe included a total of 80 ovarian cancer cases contributing 80 serum samples and compared 40 serum samples from cases with samples collected <2 years prior to diagnosis with 40 serum samples from cases with sample collection ≥2 to 7 years. We employed the extreme gradient boosting (XGBoost) algorithm to train a binary classification model using 70% of the available data, while the model was tested on the remaining 30% of the dataset.ResultsThe performance of the model was evaluated using repeated holdout validation. The previously established set of miRNAs achieved a median area under the receiver operating characteristic curve (AUC) of 0.771 in the test sets. Four out of 14 miRNAs (hsa-miR-200a-3p, hsa-miR-1246, hsa-miR-203a-3p, hsa-miR-23b-3p) exhibited higher expression levels closer to diagnosis, consistent with the previously reported upregulation in cancer cases, with statistical significance observed only for hsa-miR-200a-3p (beta=0.14; p=0.04). DiscussionThe discrimination potential of the selected models provides evidence of the robustness of the miRNA signature for ovarian cancer.